Neridronate
Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB) . Neridronate is effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy, and bone metastases[1][2].
Product Specifications
CAS Number
79778-41-9
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/neridronate.html
Purity
98.0
Solubility
H2O : 5 mg/mL (ultrasonic; warming; adjust pH to 8 with NaOH; heat to 60°C)
Smiles
OC(P(O)(O)=O)(CCCCCN)P(O)(O)=O
Molecular Formula
C6H17NO7P2
Molecular Weight
277.15
Precautions
H302, H315, H319, H335
References & Citations
[1]Gatti D, et al. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag. 2013;9:139-47.|[2]Guiducci L, et al. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. Int J Endocrinol. 2019 Feb 6;2019:9802827.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2054726-01 0.1 mL
FITC-Linked Polyclonal Antibody to Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 1 (LILRB1)
Sign In for Pricing
View Details